Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

    NEXT STORY
    Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
    PREV STORY
    G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

    author_avatar
    NASDAQ Market News

    Kidney Stones Management Market will surge at 4.6% CAGR to hit $2 billion by 2024: Global Market Insights, Inc.

    Ultrasound segment of kidney stones management market will expand at 5.4% CAGR during the ...

    author_avatar
    NASDAQ Market News

    Chembio Diagnostics Reports First Quarter 2019 Financial Results

    author_avatar
    NASDAQ Market News